Overview
160 HEALTH (2656)
160 Health International Limited wholesales and retails pharmaceutical and healthcare products in China. Thedevelops Healthcare 160 Platform, an online healthca...
- Open
- 2.910
- High
- 2.935
- Low
- 2.590
- Prev. Close
- 2.865
- Volume
- 19.55M
- Turnover
- 52.81M
- Avg Price
- 2.701
- Bid/Ask Ratio
- -54.93%
- Amplitude
- 12.04%
- 52wk High
- 158.400
- Volume Ratio
- 5.16
- Turnover Ratio
- 5.63%
- 52wk Low
- 2.105
- HK Mkt Cap
- 906.30M
- Market CapHKD
- 906.30M
- P/ETTM
- Loss
- P/EDynamic
- 184.18
- P/EStatic
- --
- EPSTTM
- -0.172
- EPSDynamic
- 0.0142
- EPSStatic
- --
- BVPS
- 0.79
- P/B
- 3.29
- HK Shares
- 347.24M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 347.24M
- Min lot size
- 250
- Currency
- HKD
Daily Events
- Nov, 16
Health 160 (2656.HK) spiked then faded to HK$2.605, down 9.08% from HK$2.865, opening at HK$2.910 near the session high and sliding to HK$2.590 in the afternoon session on 19.3 million shares. The pullback follows a 22.57% advance driven by its first AI-computing order and Barclays lifting its stake to 9.8%, with the stock giving back 17.08% this week, while an earlier proposal to change auditors had already triggered a one-day 12% drop. Q2 2026 revenue fell 11.67% year on year to HK$184.1 million, yet net profit rose 131.12% to HK$1.23 million and operating income 222.28% to HK$3.21 million. The shares trade below MA20 of HK$2.825 and MA60 of HK$5.322, down 95.56% year to date, 98.36% below the 52-week high of HK$158.4 and only 23.75% above the October 21 low of HK$2.105. Revenue contraction still limits how far profit improvement carries into the share price.
- Nov, 13
After rallying 22.57% last week, 160 Health reversed intraday and closed 6.4% lower at HK$2.865, tagging HK$3.080 in the morning before sliding to HK$2.705 in the afternoon on 41.77 million shares worth about HK$122 million and a 12.03% turnover rate, as profit-taking outweighed Barclays lifting its stake to 9.8%. Fundamentals cut against the tape: Q2 2026 revenue fell 11.67% year on year to HK$184.1 million, yet net profit rose 131.12% to HK$1.23 million, operating income jumped 222.28% to HK$3.21 million and EPS gained 125.69% to HK$0.0035. The price position remains depressed, down 95.12% year to date and 98.19% below the 52-week high of HK$158.4, with the close just above the MA20 of HK$2.818 but far under the MA60 of HK$5.442. Though the October 21 low of HK$2.105 has not been retested, and the RMB42 million AI computing contract remains a business thread.
- Nov, 12
Health 160 fell 7.4% to HK$3.060 in a spike-and-fade session that opened at HK$3.300 and slid from the intraday high of HK$3.330 to the session low at the close, on HK$130 million turnover and an 11.68% turnover rate; the drop follows last week's 22.57% gain, when Barclays lifted its stake to 9.8%, while an earlier proposal to change auditors had already knocked the shares 12% in one day. Q2 2026 revenue of HK$184.1 million fell 11.67% year on year, yet net profit of HK$1.23 million rose 131.12% and operating income gained 222.28%, leaving a net margin of just 0.67% and improvement off a very low base. The price sits awkwardly: down 94.78% year to date and 98.07% below the 52-week high of HK$158.40, though 45.37% above the HK$2.105 low and above the MA20 of HK$2.80, still far under the MA60 of HK$5.555, with price-to-book at 3.86x. A RMB42 million AI computing contract signed in October remains the narrative anchor.
- Nov, 11
Health 160 International reversed an early gain, touching HK$3.645 at 10:19 BJT before sliding through the afternoon to HK$3.285 at 15:55 and closing at HK$3.325, down 2.9% on a 16.8% turnover rate, as investors booked profits on the prior week's 22.57% rally driven by Barclays raising its stake to 9.8%, while the earlier proposal to change auditors still weighed. Q2 2026 revenue fell 11.67% yoy to HK$184.1 million, yet net profit rose 131.12% to HK$1.23 million on a thin 0.67% net margin, with operating profit up 222.28% to HK$3.21 million. The stock sits above its MA20 of HK$2.788 but far below the MA60 of HK$5.67, down 94.34% year-to-date, 97.9% below the March 17 high of HK$158.4 and 57.7% above the October 21 low of HK$2.105, with a PB of 4.19. Still, the first RMB42 million AI computing order and Barclays' 9.8% holding remain near-term references.
- Nov, 9
Health 160 opened higher, dipped to HK$3.300, spiked to HK$3.740 by 11:31 BJ, then faded through the afternoon to HK$3.45, down about 2.3% from the prior close of HK$3.53 on HK$220 million turnover and an 18.1% turnover rate. Barclays raised its stake to 9.8% through purchases at roughly HK$3.18 and HK$3.26 a share, with southbound holdings up nearly 22%, flows that earlier drove a 14%-plus single-day jump and a 22.57% weekly gain, though the proposed change of auditor triggered a 12% slide and intraday swings of +6% and -6%. Q2 revenue fell 11.67% yoy to HK$184.1 million while net profit rose 131% to HK$1.23 million and operating income 222% to HK$3.21 million. The stock sits 97.8% below its 52-week high of HK$158.4 and down 94.1% YTD, above MA20 of 2.747 but far under MA60 of 5.909, with negative PE and PB of 4.35. Though a 0.67% net margin leaves little earnings cushion.
